Clinical trials: Nivolumab
Stage II Melanoma
A Phase 2 Clinical Trial of Neoadjuvant Relatlimab and Nivolumab in High Risk, Clinical Stage II Cutaneous Melanoma
Neoadjuvant therapy is feasible in stage II melanoma, and the dual inhibition of the distinct LAG-3 and PD-1 checkpoint pathways with relatlimab and nivolumab has a synergistic effect in the tumour microenvironment leading to a…
- Trial name
- Neo ReNi II (NCT05418972)
- Testing
- Relatlimab and nivolumab fixed dose combination (FDC)
- Where
- Australia
- Volunteers
- 20 people
- Sponsor
- Melanoma Institute Australia
Metastatic Cancer
An Open Label Phase II Study Combining Nivolumab and Celecoxib in Patients With Advanced " Cold " Solid Tumors
This is an open-label study to evaluate the safety and the anti-tumor activity of the combination of nivolumab and celecoxib. The total numbers of participants to be enrolled will be up to 68 participants, depending on the…
- Trial name
- NICE-COMBO (NCT03864575)
- Testing
- Celecoxib 400 mg
- Where
- Belgium
- Volunteers
- 68 people
- Sponsor
- Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Metastatic Melanoma
Nivolumab +/- Ipilimumab Immunomonitoring in Metastatic Melanoma
This is an open bi-centric prospective non-randomized study in patients with metastatic melanoma treated with a first line treatment of Nivolumab +/- Ipilimumab.
- Trial name
- IMMUNONIVO (NCT03225365)
- Testing
- Blood and biopsy sampling
- Where
- France
- Volunteers
- 5 people
- Sponsor
- Hospices Civils de Lyon
Hepatocellular Carcinoma
Lenvatinib Plus Nivolumab Versus Lenvatinib for Advanced Hepatocellular Carcinoma With Hepatitis B Virus Infection
The purpose of this study is to investigate the efficacy and safety of lenvatinib plus nivolumab compared with lenvatinib monotherapy for patients with advanced hepatitis B virus infection-related hepatocellular carcinoma.
- Trial name
- NCT04044651
- Testing
- Lenvatinib, Nivolumab
- Where
- 5 sites in China
- Sponsor
- Shi Ming
Diffuse Pleural Mesothelioma, Gastroesophageal Carcinoma
A Study of BMS-986504 With Standard-of-Care Therapy for People With Solid Tumor Cancer
The researchers are doing this study to test the safety of BMS-986504 in combination with standard disease-specific anticancer medication in people with metastatic/advanced unresectable MTAP-deleted solid tumor cancer.
- Conditions
- Diffuse Pleural Mesothelioma, Gastroesophageal Carcinoma, Urothelial Carcinoma
- Trial name
- NCT07532902
- Testing
- BMS-986504, Ipilimumab, Nivolumab
- Where
- 7 sites in United States
- Volunteers
- 60 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Esophageal Cancer
Liposomal iRInotecan, Carboplatin or oXaliplatin for Esophagogastric Cancer
This is a multi-center, open label, randomized phase II trial for patients with previously untreated metastatic or locally advanced esophagogastric cancer, using a pick the winner design to identify the best combination therapy…
- Trial name
- LyRICX (NCT03764553)
- Testing
- Liposomal Irinotecan, Carboplatin, Capecitabine
- Where
- 34 sites in Netherlands
- Volunteers
- 320 people
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
HER2-negative, Gastroesophageal Junction
Study of Denikitug (GS-1811) Given Alone or With Nivolumab or Chemotherapy in Adults With Metastatic Gastric, Gastroesophageal Junction (GEJ), and Esophageal Adenocarcinomas
The goal of this clinical study is to learn more about the study drug, Denikitug (DEN, GS-1811), to evaluate the efficacy and safety of Denikitug Monotherapy and Denikitug-based combinations in in participants with human…
- Conditions
- HER2-negative, Gastroesophageal Junction, Esophageal Adenocarcinoma, Gastric Adenocarcinoma
- Trial name
- NCT07546812
- Testing
- Denikitug, Nivolumab, Ramucirumab
- Where
- 15 sites in United States, Australia and 3 more
- Volunteers
- 120 people
- Sponsor
- Gilead Sciences
Recurrent Non-Small Cell Lung Carcinoma, Stage III Non-Small Cell Lung Cancer
Nivolumab and Metformin Hydrochloride in Treating Patients With Stage III-IV Non-small Cell Lung Cancer That Cannot Be Removed by Surgery
The purpose of this study is to find the benefits of combining nivolumab with metformin in advanced non-small cell lung cancer with and without prior treatment with immunotherapy.
- Conditions
- Recurrent Non-Small Cell Lung Carcinoma, Stage III Non-Small Cell Lung Cancer, Stage IIIA Non-Small Cell Lung Cancer, Stage IIIB Non-Small Cell Lung Cancer
- Trial name
- NCT03048500
- Testing
- Laboratory Biomarker Analysis, Metformin Hydrochloride, Nivolumab
- Where
- 2 sites in United States
- Volunteers
- 17 people
- Sponsor
- Northwestern University
BCC - Basal Cell Carcinoma, Immune Response
Laser Immunotherapy With and Without Topical Anti-PD1 in Basal Cell Carcinomas
The study aim is to assess the immunological and clinical response in basal cell carcinoma (BCC) treated with ablative fractionated laser (AFL) as monotherapy and compare with BCC treated with combination-therapy of AFL and the…
- Conditions
- BCC - Basal Cell Carcinoma, Immune Response, Immunotherapy, Ablative Fractionated Laser
- Trial name
- NCT04570683
- Testing
- Nivolumab 10 MG/ML, Ablative fractionated laser
- Where
- Denmark
- Volunteers
- 30 people
- Sponsor
- Bispebjerg Hospital
Circulating Tumor Cells
Investigation of Circulating Tumor Cells From Cancer Patients Undergoing Radiation Therapy
The purpose of this study is to investigate the level of Circulating Tumor Cells (CTCs) in cancer patients before and after undergoing treatment regimens where the primary treatment modality is radiation therapy (XRT).
- Trial name
- NCT02449837
- Testing
- Blood draw
- Where
- United States
- Volunteers
- 162 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction , or Esophageal Adenocarcinoma, Metastatic Gastric Cancer
Symbiotic-GI-16: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal Cancer
This study is being done to learn more about a new medicine called PF-08634404 and how well it works when given with chemotherapy to people with gastroesophageal cancer that is locally advanced (spread to nearby tissues) or has…
- Conditions
- Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction , or Esophageal Adenocarcinoma, Metastatic Gastric Cancer, Gastroesophageal Junction Cancer, Esophageal Adenocarcinoma
- Trial name
- NCT07392892
- Testing
- PF-08634404, Chemotherapy, Nivolumab
- Where
- 102 sites in United States, Canada and 8 more
- Volunteers
- 840 people
- Sponsor
- Pfizer
Colorectal Cancer Metastatic, Pancreatic Cancer Metastatic
Ipilimumab, Maraviroc and Nivolumab in Advanced Metastatic Colorectal and Pancreatic Cancer the LUMINESCENCE Trial
The study will be conducted in compliance with Good Clinical Practices (ICH-GCP) and the Declaration of Helsinki, and in accordance with applicable legal and regulatory requirements, including archiving of essential documents.
- Trial name
- NCT04721301
- Testing
- Nivolumab plus Ipilimumab plus Maraviroc
- Where
- Germany
- Volunteers
- 50 people
- Sponsor
- University Hospital Heidelberg
High Grade Glioma, Diffuse Intrinsic Pontine Glioma
Study of Relatlimab and Nivolumab (Opdualag) in Replication Repair Deficient HGG and DIPG
The goal of this study is to further evaluate feasibility and tolerability of Opdualag for patients with replication repair deficient HGG, including DIPG.
- Conditions
- High Grade Glioma, Diffuse Intrinsic Pontine Glioma, WHO Grade 3 Glioma, WHO Grade 4 Glioma
- Trial name
- NCT07644312
- Testing
- Opdualag
- Volunteers
- 12 people
- Sponsor
- Nationwide Children's Hospital
Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma
Nivolumab With or Without Ipilimumab in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
This randomized phase II trial studies how well nivolumab works with or without ipilimumab in treating patients with epithelial ovarian, primary peritoneal, or fallopian tube cancer that has not responded after prior treatment…
- Conditions
- Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
- Trial name
- NCT02498600
- Testing
- Ipilimumab, Nivolumab
- Where
- 201 sites in United States
- Volunteers
- 100 people
- Sponsor
- National Cancer Institute (NCI)
Uterine Cancer, Endometrial Carcinoma
A Study of Nivolumab in Selected Uterine Cancer Patients
The purpose of this study is to test the safety of nivolumab and find out what affects, if any, nivolumab has on people and their risk of gynecologic cancer.
- Conditions
- Uterine Cancer, Endometrial Carcinoma, Carcinosarcoma, Leiomyosarcoma
- Trial name
- NCT03241745
- Testing
- Nivolumab
- Where
- 8 sites in United States
- Volunteers
- 35 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Metastatic Renal Cell Carcinoma, Brain Metastases
A Study of Cabozantinib and Nivolumab With Radiation Therapy for People With Renal Cell Carcinoma That Has Spread to the Brain
The purpose of this study is to find out whether the combination of cabozantinib, nivolumab, and radiation therapy is a safe and effective treatment that causes few or mild side effects in people with renal cell cancer that has…
- Trial name
- NCT06132945
- Testing
- Cabozantinib, Nivolumab, Stereotactic Radiosurgery (SRS)
- Where
- 7 sites in United States
- Volunteers
- 2 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Mesothelioma
Nivolumab Monotherapy or Nivolumab Plus Ipilimumab, for Unresectable Malignant Pleural Mesothelioma (MPM) Patients
The sponsor raise the hypothesis that inhibition of immune PD-1+/- CTLA-4 check-point(s) would delay tumor progression in patients with unresectable MPM, experiencing disease progression after one or two lines of chemotherapy…
- Trial name
- MAPS2 (NCT02716272)
- Testing
- Nivolumab, Nivolumab + Ipilimumab
- Where
- 22 sites in France
- Volunteers
- 125 people
- Sponsor
- Intergroupe Francophone de Cancerologie Thoracique
Cholangiocarcinoma Non-resectable
DEB-TACE, Lenvatinib and Anti-PD(L)1 Antibody as Conversion Therapy for Intrahepatic Cholangiocarcinoma
The aim of this study is to the efficacy, prognosis, adverse effects, and factors for predicting therapeutic effects and clinical prognosis of combined therapy of Drug-eluting Beads-transarterial chemoembolization (DEB-TACE)…
- Trial name
- CCGLC-009 (NCT06194695)
- Testing
- drug eluting beads-transcatheter arterial chemoembolization, envatinib plus anti-PD(L)1
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Ze-yang Ding, MD
Gastric Cancer
A Study to Evaluate the Efficacy and Safety of ONO-4538 in Combination With Ipilimumab and Chemotherapy in Chemotherapy-naïve Participants With HER2-negative Unresectable Advanced or Recurrent Gastric Cancer (Including Esophagogastric Junction Cancer)
This study is to compare and evaluate the efficacy and safety of ONO-4538 in combination with ipilimumab and chemotherapy versus chemotherapy in chemotherapy-naïve participants with HER2-negative unresectable advanced or…
- Trial name
- NCT05144854
- Testing
- ONO-4538, Ipilimumab, Oxaliplatin
- Where
- 57 sites in Japan, South Korea and 1 more
- Volunteers
- 626 people
- Sponsor
- Ono Pharmaceutical Co., Ltd.
Metastatic Triple-negative Breast Cancer
Saci Nivo Rela for TNBC
This is a randomized, open-label, phase Ib study to assess safety and efficacy of sacituzumab govitecan plus nivolumab or sacituzumab govitecan plus a fixed dose combination of nivolumab and relatlimab in patients with any…
- Trial name
- SIMONE (NCT06963905)
- Testing
- Relatlimab FDC + Nivolumab, Sacituzumab Govitecan (SG), Nivolumab
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Yale University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.